Targeting cell cycle and hormone receptor pathways in cancer

Oncogene

Volumn 32, Issue 48, 2013, Pages 5481-5491

  Comstock, C E S ^a   Augello, M A ^a   Goodwin, J F ^a   De Leeuw, R ^a   Schiewer, M J ^a   Ostrander, W F ^a   Burkhart, R A ^a   McClendon, A K ^a   McCue, P A ^a   Trabulsi, E J ^a   Lallas, C D ^a   Gomella, L G ^a   Centenera, M M ^b   Brody, J R ^a   Butler, L M ^b   Tilley, W D ^a   Knudsen, K E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cyclin dependent kinase; PD 0332991; Prostate cancer; Retinoblastoma protein; Tumor explants

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PALBOCICLIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEASIBILITY STUDIES; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ANDROGEN; RETINOBLASTOMA; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889087652     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.83     Document Type: Article

References (65)

1. Knudsen KE, Kelly WK. Outsmarting androgen receptor: Creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab 2011; 6: 483-493
2. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: Understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol 2010; 20: 258-266
3. Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle: Mechanisms and cancer relevance. Mol Cell Endocrinol 2012; 352: 34-45
4. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005; 5: 366-373
5. Diaz-Padilla I, Siu LL, Duran I. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs 2009; 27: 586-594
6. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16: 36-43
7. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 2011; 226: 341-349
8. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L et al. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997; 3: 273-279
9. Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996; 9: 1143-1168
10. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-2999
11. Liu G, Gandara DR, Lara Jr. PN, Raghavan D, Doroshow JH, Twardowski P et al. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004; 10: 924-928
12. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388-2406
13. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427-1438
14. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K et al. Treatment of growing teratoma syndrome. N Engl J Med 2009; 360: 423-424
15. Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006; 108: 1744-1750
16. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T et al. Pharmacologic inhibition of CDK4/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007; 110: 2075-2083
17. Rodriguez-Otero P, Roman-Gomez J, Vilas-Zornoza A, Jose-Eneriz ES, Martin- Palanco V, Rifon J et al. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family. Br J Haematol 2011; 155: 73-83
18. Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I et al. A novel therapeutic combination using PD 0332991 and bortezomib: Study in the 5T33MM myeloma model. Cancer Res 2008; 68: 5519-5523
19. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006; 66: 7661-7667
20. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77
21. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H et al. ERalphadependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011; 1: 338-351
22. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012; 104: 476-487
23. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapyresistant breast cancer. Endocr Relat Cancer 2011; 18: 333-345
24. Zhang C, Yan Z, Arango ME, Painter CL, Anderes K. Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435- HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 2009; 15: 238-246
25. Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, Zhang Q et al. [18F]FLT-PET imaging does not always light up proliferating tumor cells. Clin Cancer Res 2012; 18: 1303-1312
26. Sutherland JJ, Low J, Blosser W, Dowless M, Engler TA, Stancato LF. A robust highcontent imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther 2011; 10: 242-254
27. Heijink DM, Fehrmann RS, de Vries EG, Koornstra JJ, Oosterhuis D, van der Zee AG et al. A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. Oncogene 2011; 30: 2026-2036
28. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van den Brink GR et al. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 2010; 70: 8149-8158
29. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73
30. Ismail A, Bandla S, Reveiller M, Toia L, Zhou Z, Gooding WE et al. Early G cyclindependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. Clin Cancer Res 2011; 17: 4513-4522
31. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA 2010; 107: 11501-11506
32. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010; 70: 3228-3238
33. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer 2011; 104: 1862-1868
34. Leonard JP, Lacasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597-4607
35. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18: 568-576
36. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure. Oncogene 2010; 29: 4018-4032
37. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 2011; 17: 1591-1602
38. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-682
39. Knudsen ES, Knudsen KE. Tailoring to RB: Tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8: 714-724
40. Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D et al. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007; 102: 869-877
41. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620-634
42. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474: 230-234
43. Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A et al. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem 2011; 286: 8117-8127
44. Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, Dicker AP et al. mTOR is a selective effector of the radiation therapy response in androgen receptorpositive prostate cancer. Endocr Relat Cancer 2012; 19: 1-12
45. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2011; 18: 666-677
46. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120: 4478-4492
47. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-3668
48. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Grana X et al. Proliferative suppression by CDK4/6 inhibition: Complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010; 138: 1920-1930
49. Centenera MM, Gillis JL, Hanson A, Jindal S, Taylor RA, Risbridger G et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18: 3562-3570
50. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50: 465-472
51. Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA, Akslen LA. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000; 88: 416-424
52. Martin JM, Supiot S, Berthold DR. Pharmacotherapeutic management of locally advanced prostate cancer: Current status. Drugs 2011; 71: 1019-1041
53. Lolli G, Lowe ED, Brown NR, Johnson LN. The crystal structure of human CDK7 and its protein recognition properties. Structure 2004; 12: 2067-2079
54. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature 1993; 363: 595-602
55. Day PJ, Cleasby A, Tickle IJ, O'Reilly M, Coyle JE, Holding FP et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA 2009; 106: 4166-4170
56. Brotherton DH, Dhanaraj V, Wick S, Brizuela L, Domaille PJ, Volyanik E et al. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 1998; 395: 244-250
57. Lu H, Schulze-Gahmen U. Toward understanding the structural basis of cyclindependent kinase 6 specific inhibition. J Med Chem 2006; 49: 3826-3831
58. Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA 2005; 102: 5156-5161
59. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 2011; 8: 562-568
60. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256
61. Mostaghel EA, Plymate S. New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am 2011; 40: 625-642
62. Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: Rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010; 14: 1199-1212
63. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998; 273: 20213-20222
64. Korzynska A, Zychowicz M. A method of estimation of the cell doubling time on the basis of cell culture monitoring data. Biocybernet Biomed Engineer 2008; 28: 75-82
65. Wetherill YB, Hess-Wilson JK, Comstock CE, Shah SA, Buncher CR, Sallans L et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther 2006; 5: 3181-3190